The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs (Urinary Tract Infections), Pain Management, Allergy Symptoms and Attention Deficit Disorder (ADD/ ADHD) and Narcolepsy.
The cumulative market size for the acquired portfolio is ~USD 57 million, as per IQVIA data of 2025.
Total consideration for acquisition of the said ANDAs is USD 2.075 million (~INR 176 million).
"Two (out of the Four) ANDAs acquired are commercial products and is expected to be launched within 12 months. With access to these products, Strides will expand its portfolio of niche and difficult to manufacture products," the Company stated in a BSE filing.
Medical Dialogues team had earlier reported that Strides Pharma Global Pte. Limited (SPG), a step-down wholly-owned Subsidiary of the company in Singapore, had also entered into a Share Purchase Agreement to acquire 100 percent stake in Amexel for a nominal consideration of USD 10.
Read also: Strides Pharma Science Singapore arm to acquire 100 percent stake in Amexel
Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE Limited (532531) and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy and an institutional business to service donorfunded markets. The Company’s global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Italy (Milan), Kenya (Nairobi), and the United States (New York). The Company focuses on “difficult to manufacture” products sold in over 100 countries.
Read also: Strides Pharma Science arm gets USFDA nod for Acetaminophen and Ibuprofen Tablets
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.